FeesSafety
Pluang+

KORU Medical Systems rated Buy at $3.50 as Q3 shows recovery and FY26 revenue guidance raised.

Company Fundamentals
13 Nov 2026, 15:56 WIB
Seeking Alpha
View Source
Bullish
KORU Medical Systems rated Buy at $3.50 as Q3 shows recovery and FY26 revenue guidance raised.

KORU Medical Systems received a Buy rating at $3.50 following Q3 results that indicate recovery from earlier challenges. The company raised its FY26 revenue guidance to $48.0M–$48.5M, expecting 17–18% growth and a gross margin of 63–64%. Its core SCIg business grew 11.2% year-over-year with a 500 basis point margin expansion, supported by pipeline initiatives for future growth. Key risks include dependence on international expansion, oncology, non-Ig drugs, and reimbursement exposure.

KORU Medical Systems' Q3 update includes a raised FY26 revenue guidance to $48.0M–$48.5M, with expected growth of 17–18% and a gross margin of 63–64%. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 13, 2026 20:42 WIB: out of 150 priced US health stocks, 107 rose and 39 fell. Notable movers include HRTX at USD 0.35 (+5.80%, typical hold time 39 days, Pluang order activity 52% Sell / 48% Buy), CTXR at USD 0.51 (-4.21%, typical hold time 19 days, Pluang order activity 84% Sell / 16% Buy), and TNGX at USD 24.00 (-3.42%, typical hold time 4 days).

More News

Beer Institute honors 16 top U.S. beer industry professionals with 2026 BEST IN BREW awards

Beer Institute honors 16 top U.S. beer industry professionals with 2026 BEST IN BREW awards

The Beer Institute recognized 16 outstanding professionals with its 2026 BEST IN BREW Honors, celebrating their exceptional contributions across brewing, supply chain, and leadership roles in the U.S. beer industry. This annual award highlights the d...

Neutral
14 minutes ago
Michelin discloses total voting rights and shares as of October 31, 2026

Michelin discloses total voting rights and shares as of October 31, 2026

Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...

Company Fundamentals
Neutral
1 hour ago
Michelin reports total voting rights and shares as of October 31, 2026, including treasury shares.

Michelin reports total voting rights and shares as of October 31, 2026, including treasury shares.

Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...

Company Fundamentals
Neutral
1 hour ago
KeyBanc cuts YETI price target to $49 as sales growth forecast drops to 6% amid cautious consumers.

KeyBanc cuts YETI price target to $49 as sales growth forecast drops to 6% amid cautious consumers.

KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...

Analyst Insights
Neutral
1 hour ago
Bernstein lowers Applied Materials price target to $600 despite strong AI chip demand.

Bernstein lowers Applied Materials price target to $600 despite strong AI chip demand.

Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...

Analyst Insights
Bearish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App